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members with a cholesterol marker in their profile were invited to participate via
email; enrollment was supplemented with digital outreach. Interested individuals
clicked a link to access study information and screen based on self-reported diag-
nosis and willingness to have data linked to the SAIL warehouse. Study subjects
completed an on-line questionnaire and provided identifiers to be used only for
data linkage. The SAIL system’s NHS Trusted Third Party converted study identifi-
ers into pseudo-identifiers allowing the linkage of patient-reported data with elec-
tronic health data. RESULTS: A total of 240 enrolled within 6 weeks: 98 fromMedi-
Guard and 142 through other digital channels. NHS matched 226 of 240 (94%) to a
pseudo-identifier (69 exactly, 157with probability0.9). A total of 91 of 226matched
(41%) had at least one primary care record in SAIL and nearly all (89 of 91, 98%) had
data suggesting a cholesterol problem.Matching cholesterol test dates (6months)
were located for 66 of 89 (74%, Spearman correlation0.786, p0.0001) and there
was a high positive correlation of total cholesterol values amongst the 1/3 of pa-
tients able to self-report data (n28, Pearson correlation0.785, P0.0001). Addi-
tional analyses exploring markers that predict patient’s ability to self-report are
underway. CONCLUSIONS: This study demonstrates the feasibility of linking pa-
tient reported data with electronic health information. UK individuals are inter-
ested in participating, provide truthful information, and their patient-reported
data can be linked to electronic information in the SAIL warehouse in Wales, thus
offering new research possibilities.
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OBJECTIVES: To determine the relationship between postsurgical opioid use
through morphine equivalent dose (MED) and ileus was assessed in patients un-
dergoing commonGI surgeries, and the impact of ileus on length of stay (LOS), total
visit cost, and 30-day readmissions.METHODS: The Premier database was queried
to identify adult inpatients discharged between 2008 and 2010 who received post-
surgical opioids following open colectomy, laparoscopic colectomy or cholecystec-
tomy. Ileus was identified using ICD-9 diagnosis codes and postsurgical (MED) was
calculated. Descriptive statistics including the outcomes of LOS, total visit cost, and
30-day readmissionwere obtained. For comparing patients with andwithout ileus,
t-tests for continuous variables and chi-squared tests for categorical variableswere
used (alpha 0.05). RESULTS: There were 138,068 patients, average age of 56.8 (SD
18.5) that met the study criteria. Overall, 10.3% of patients had an ileus, ranging
from 3.2% in laparoscopic cholecystectomy to 20.6% in open colectomy. The unad-
justed mean LOS (7.3 days p0.0001), total visit cost ($15,928 p0.0001), and
readmissions (5.9% p0.0001) were higher for patients with ileus compared to
those without ileus. Of note, the total visit costs were 3 times higher among pa-
tients experiencing an ileus after laparoscopic cholecystectomies compared to 2
times greater for other GI procedures complicated by ileus, than patients without
ileus. Patients with higher (abovemedian) MED compared to lower (belowmedian)
MED had a 2 fold greater odds of ileus (OR 2.0 95% CI 1.92 – 2.06; p 0.0001).
CONCLUSIONS: Occurrence of ileus significantly increased the total cost across all
GI surgeries even in surgeries where the incidence of ileus is less common. In this
study, higher dosages of opioids are associated with the incidence of ileus; more
research is needed to determine whether strategies to decrease opioid use im-
proves outcomes and reduces ileus.
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OBJECTIVES: To quantify the incidence of hepatotoxicity associated with antithy-
roid drugs and analyze the relative hepatotoxicity risk of methimazole (MMI) and
carbimazole (CBM) compared to propylthiouracil (PTU) among patients with
hyperthyroidism. METHODS: A retrospective population-based cohort study was
conducted by analyzing data from the Taiwan National Health Insurance Research
Databases between January 1, 2004 andDecember 31, 2008. Patients diagnosedwith
hyperthyroidism (ICD-9-CM codes 242.xx, 775.3) and initially receiving antithyroid
drugs were identified as the study cohort, in which MMI/CBM and PTU users were
further specified. The two groups were followed up to observe the occurrence of
hepatotoxic events, including jaundice, cholestasis, noninfectious hepatitis, acute
liver failure, and liver transplant. Crude incidence rates of the hepatotoxicity per
1000 person-years were calculated. Cox proportional hazard models were em-
ployed to estimate crude and adjusted hazard ratios (HRs) of hepatotoxicity risks
for MMI/CBM relative to PTU. RESULTS: The study cohort comprised a total of
71,379 patientswith hyperthyroidism. The hepatitis outcomewas observed to have
the highest incidence in bothMMI/CBM and PTU users, with a rate of 11.44 and 9.89
events per 1000 person-years, respectively. The comparative risk analyses indi-
cated that use of MMI/CBM exerted a significantly increased risk of hepatitis than
use of PTU (adjusted HR, 1.23; 95% CI, 1.03-1.47). Additionally, MMI/CBM prescribed
at an average daily dose greater than 10 mg further enhanced the risk of jaundice
(adjusted HR, 1.99; 95% CI, 1.13-3.49) and hepatitis (adjusted HR, 2.33; 95% CI, 1.93-
2.82) to a larger degree than any use of PTU. CONCLUSIONS: Hepatitis is the most
frequently occurring hepatotoxicity outcome for both MMI/CBM and PTU users.
Notably, MMI/CBM is associated with a higher risk of hepatitis than PTU in a dose-
dependent manner. Health care professionals should be vigilant to the symptoms
of hepatitis for patients prescribed antithyroid drugs, especially for those receiving
higher doses of MMI/CBM.
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OBJECTIVES: To develop and validate algorithms that can identify diverticulitis
patients with high reliability through the use of electronic medical records (EMRs).
METHODS:UsingKPSC EMRs of adults (18 years old)with ICD-9 diagnosis codes of
diverticulitis (562.11, 562.13) between January 1, 2008 and August 30, 2009, we gen-
erated random samples for pilot-testing (N700) and validation purposes
(N1,300) respectively. Both samples were stratified by inpatient (IP), emergency
room (ER), and outpatient (OP) treatment settings. For each setting, we constructed
and analyzed 10 different algorithms based on EMR variables such as diverticulitis
diagnosis code, antibiotics use, computed tomography (CT), and prior diverticulo-
sis diagnosis. Evidence of diverticulitis was verified and confirmed throughmanual
chart review by trained research associates. Agreement between each EMR algo-
rithm and chart confirmation was compared by estimating sensitivity and positive
predictive value (PPV). We defined acceptable sensitivity and PPV as 80%.
RESULTS: ICD-9 diagnosis in combinationwith use of antibiotics within 7 dayswas
the most accurate algorithm to identify diverticulitis in patients treated in OP and
ER settings. For those admitted inpatients, the most accurate algorithm was the
combination of diagnosis code with lower abdominal CT recorded within 7 days of
diagnosis. In the pilot-testing sample, sensitivity and PPV were (94.7%, 81.7%),
(79.1%, 88.7%), and (86.7%, 82.8%) for OP, ER, and IP, respectively. In the validation
sample, sensitivity and PPV remained very high: (85.6%, 96.1%), (91.5%, 94.4%), and
(79.1%, 81.2%) for OP, ER, and IP, respectively. CONCLUSIONS: The KPSC algorithms
developed to identify diverticulitis cases using EMR resulted in high accuracy for
three different treatment settings. The validity of these algorithms should be fur-
ther evaluated in other systems.
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OBJECTIVES: In a field wheremany disciplines, such as clinicians, epidemiologists,
economists and statisticians, interact frequently, a tool to communicate drug
treatment patterns clearly and effectively through graphical means is a necessity-
.Using data visualization techniques, we aim to clearly present treatment patterns
among patients with ulcerative colitis (UC). METHODS: Using the 100% national
Medicare data with Part D information, patients over age 65 with at least one UC
diagnosis were selected for the study. We identified patients who initiated therapy
with tumor necrosis factor (TNF) and non-TNF therapies. For 2 years after the
initiation of biologics, we determined the treatment patterns such as switching to
another TNF, non-TNF, and discontinuation. Using a processing language, we cre-
ated a data visualization tool to demonstrate how patients change their drug pat-
tern after first, second and third switches. RESULTS: A total of 1643 UC patients
initiated their therapy with a TNF agent. 3.47% of these patients switched to an-
other TNF, 1.40% switched to a non-TNF, 61.17% discontinued their therapy, and
33.96% continued their initial therapy. Among patients who switched to another
TNF, 49.12% remained on the switched therapy, 40.35% discontinued therapy,
10.53% switched to another TNF, and no patients switched to a non-TNF. 2,628 UC
patients initiated their therapy with a non-TNF, of which 0.49% switched to an
anti-TNF, 0.19% switched to non-TNF, 97.98% discontinued therapy and 1.33% con-
tinued their initial therapy. CONCLUSIONS: Treatment patterns can be difficult to
present, especially when analyzing several data years and among various switch-
ing patterns. Data visualization tools can help researchers present complicated
results, such as treatment patterns, effectively to a varied audience.
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OBJECTIVES: In health outcomes research, wheremany different disciplines inter-
act frequently, a tool to communicate treatment patterns clearly and effectively
through graphical means is a necessity. Using data visualization techniques, we
aimed to present treatment patterns of patients with Crohn’s disease in a visual
manner. METHODS: This study used 100% national Medicare data with Part D
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